Immunic

Historical price data

Immunic is a clinical-stage biotech focused on developing oral therapies for autoimmune and inflammatory diseases, with a pipeline of eight candidates. Its core strategy is advancing vidofludimus calcium, a DHODH inhibitor, through pivotal trials in multiple sclerosis and ulcerative colitis. The company aims to establish a new standard of care with convenient, orally administered treatments that could improve patient access and outcomes. Success hinges on clinical data readouts, regulatory milestones, and strategic execution in a competitive market.

Focused on oral small molecules that selectively inhibit immunology targets, primarily dihydroorotate dehydrogenase (DHODH), to modulate immune cell proliferation and inflammation with a favorable safety profile.

Immunic faces entrenched competition from large-cap biopharma companies with approved injectable biologics and oral therapies in MS and IBD. Its differentiation hinges on demonstrating a superior efficacy/safety profile for vidofludimus calcium versus existing oral DHODH inhibitors and competing mechanisms.